PE20200333A1 - Compuestos y metodos para tratar infecciones bacterianas - Google Patents

Compuestos y metodos para tratar infecciones bacterianas

Info

Publication number
PE20200333A1
PE20200333A1 PE2019002309A PE2019002309A PE20200333A1 PE 20200333 A1 PE20200333 A1 PE 20200333A1 PE 2019002309 A PE2019002309 A PE 2019002309A PE 2019002309 A PE2019002309 A PE 2019002309A PE 20200333 A1 PE20200333 A1 PE 20200333A1
Authority
PE
Peru
Prior art keywords
compounds
methods
bacterial infections
treat bacterial
alkyl
Prior art date
Application number
PE2019002309A
Other languages
English (en)
Spanish (es)
Inventor
Janelle Comita-Prevoir
Thomas Francois Durand-Reville
Satenig Guler
Jan Romero
Mark Sylvester
Ruben Tommasi
Camilo Velez-Vega
Xiaoyun Wu
Jing Zhang
Original Assignee
Entasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entasis Therapeutics Inc filed Critical Entasis Therapeutics Inc
Publication of PE20200333A1 publication Critical patent/PE20200333A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE2019002309A 2017-05-08 2018-05-08 Compuestos y metodos para tratar infecciones bacterianas PE20200333A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762502867P 2017-05-08 2017-05-08
PCT/US2018/031593 WO2018208769A1 (en) 2017-05-08 2018-05-08 Compounds and methods for treating bacterial infections

Publications (1)

Publication Number Publication Date
PE20200333A1 true PE20200333A1 (es) 2020-02-14

Family

ID=62223332

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019002309A PE20200333A1 (es) 2017-05-08 2018-05-08 Compuestos y metodos para tratar infecciones bacterianas

Country Status (27)

Country Link
US (1) US11046694B2 (https=)
EP (1) EP3630111B1 (https=)
JP (1) JP7058322B2 (https=)
KR (1) KR102611447B1 (https=)
CN (1) CN110709081B (https=)
AU (1) AU2018266640B2 (https=)
CY (1) CY1125340T1 (https=)
DK (1) DK3630111T3 (https=)
EA (1) EA038393B1 (https=)
ES (1) ES2907858T3 (https=)
HR (1) HRP20220231T1 (https=)
HU (1) HUE057592T2 (https=)
IL (1) IL270380B (https=)
LT (1) LT3630111T (https=)
MA (1) MA48743A (https=)
MX (1) MX385203B (https=)
MY (1) MY201377A (https=)
NZ (1) NZ758200A (https=)
PE (1) PE20200333A1 (https=)
PH (1) PH12019502509A1 (https=)
PL (1) PL3630111T3 (https=)
PT (1) PT3630111T (https=)
SG (1) SG11201909443YA (https=)
SI (1) SI3630111T1 (https=)
SM (1) SMT202200110T1 (https=)
TW (1) TWI791018B (https=)
WO (1) WO2018208769A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
SG11202101255UA (en) 2018-08-09 2021-03-30 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN111675641B (zh) * 2020-06-04 2023-09-08 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法
US12410166B2 (en) 2021-05-07 2025-09-09 Ningxia Academy Of Agriculture And Forestry Sciences Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors
US11814385B2 (en) 2021-06-25 2023-11-14 University Of South Florida Small molecule inhibitors targeting Clostridioides difficile sporulation
WO2025064681A1 (en) * 2023-09-19 2025-03-27 Entasis Therapeutics Inc. Compounds and methods for treating bacterial infections

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT74682A (en) 1993-12-29 1997-01-28 Pfizer Diazabicyclic neurokinin antagonists and pharmaceutical compositions containing them
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7507727B2 (en) * 2003-04-07 2009-03-24 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs and methods of using thereof
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
ES2533826T3 (es) 2008-01-18 2015-04-15 Merck Sharp & Dohme Corp. Inhibidores de beta-lactamasa
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP2921559A1 (en) 2008-06-19 2015-09-23 Astra Zeneca Holding France Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2937034B1 (fr) * 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
US9744160B2 (en) 2011-07-26 2017-08-29 Wockhardt Limited Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
EP2768503A1 (en) 2011-07-26 2014-08-27 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
RU2578370C2 (ru) 2011-08-27 2016-03-27 Вокхардт Лимитед Производные 1,6- диазабицикло [3,2,1] октан-7-она и их применение при лечении бактериальных инфекционных болезней
MX340533B (es) * 2011-08-30 2016-07-13 Wockhardt Ltd Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
EP3052497B1 (en) 2011-09-13 2017-06-28 Wockhardt Limited Nitrogen containing compounds and their use
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
EP2814483A2 (en) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
TW201343645A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑
KR20150003777A (ko) 2012-03-30 2015-01-09 큐비스트 파마슈티컬즈 인코포레이티드 이속사졸 β-락타마제 억제제
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
RU2693898C2 (ru) 2012-05-30 2019-07-05 Мейдзи Сейка Фарма Ко., Лтд. НОВЫЙ ИНГИБИТОР бета-ЛАКТАМАЗЫ И СПОСОБ ЕГО ПОЛУЧЕНИЯ
BR112015003592B1 (pt) 2012-08-25 2020-04-14 Wockhardt Ltd derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
WO2014033561A1 (en) 2012-09-03 2014-03-06 Wockhardt Limited Antibacterial compositions
WO2014122468A1 (en) 2013-02-06 2014-08-14 Astrazeneca Ab Combination therapy for the treatment of nosocomial pneumonia
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
KR102542392B1 (ko) 2014-11-17 2023-06-09 엔타시스 테라퓨틱스 리미티드 내성 박테리아 감염의 치료를 위한 배합물 치료제
CN114591223B (zh) 2016-09-16 2025-01-24 恩塔西斯治疗有限公司 β-内酰胺酶抑制剂化合物

Also Published As

Publication number Publication date
PH12019502509A1 (en) 2020-07-13
AU2018266640A1 (en) 2019-11-07
EA201992370A1 (ru) 2020-03-10
SG11201909443YA (en) 2019-11-28
ES2907858T3 (es) 2022-04-26
CY1125340T1 (el) 2024-02-16
US11046694B2 (en) 2021-06-29
TW201843152A (zh) 2018-12-16
PL3630111T3 (pl) 2022-05-23
MY201377A (en) 2024-02-21
NZ758200A (en) 2025-12-19
EA038393B1 (ru) 2021-08-20
JP7058322B2 (ja) 2022-04-21
SI3630111T1 (sl) 2022-05-31
LT3630111T (lt) 2022-03-10
MX2019013291A (es) 2020-01-15
WO2018208769A1 (en) 2018-11-15
AU2018266640B2 (en) 2022-03-03
DK3630111T3 (en) 2022-03-14
IL270380B (en) 2022-06-01
CN110709081B (zh) 2023-09-22
JP2020519687A (ja) 2020-07-02
EP3630111B1 (en) 2021-11-24
HRP20220231T1 (hr) 2022-04-29
US20200165251A1 (en) 2020-05-28
SMT202200110T1 (it) 2022-05-12
PT3630111T (pt) 2022-03-01
CA3059773A1 (en) 2018-11-15
HUE057592T2 (hu) 2022-05-28
CN110709081A (zh) 2020-01-17
KR20200005586A (ko) 2020-01-15
EP3630111A1 (en) 2020-04-08
BR112019023130A2 (pt) 2020-05-26
KR102611447B1 (ko) 2023-12-06
TWI791018B (zh) 2023-02-01
MX385203B (es) 2025-03-14
MA48743A (fr) 2020-04-08

Similar Documents

Publication Publication Date Title
PE20200333A1 (es) Compuestos y metodos para tratar infecciones bacterianas
MX2022005839A (es) Compuestos utiles como inhibidores de la proteina helios.
ECSP20044709A (es) Inhibidores de sarcómero cardíaco
MX385731B (es) Compuestos de biaril-monobactam y métodos de uso de los mismos para el tratamiento de infecciones bacterianas.
CR20170605A (es) DERIVADOS DE 3-TETRAZOLIL-BENCENO-1,2-DISULFONAMIDA COMO INHIBIDORES DE METALO -ß-LACTAMASA
MX392515B (es) Compuestos inhibidores de beta-lactamasa
JOP20200130B1 (ar) مركبات كرومان مونوباكتام لعلاج العدوى البكتيرية
CO2026002343A2 (es) Inhibidores de pi3k
CO2023013321A2 (es) Compuestos de oxoisoindolina sustituidos con piridinilo
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
MX2020003383A (es) Compuesto de griseofulvina y uso farmacéutico de este.
ECSP21011232A (es) Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende
MX2020000576A (es) Compuestos quimicos.
MX2023006176A (es) Nuevos derivados de indazol acetileno.
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
DOP2024000096A (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
MX2020008706A (es) Nuevos compuestos de opioides y sus usos.
AR131945A1 (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
EA202090357A1 (ru) Химические соединения
EA202190585A1 (ru) Производные индана для применения при лечении бактериальной инфекции
EA201591697A1 (ru) Гидрохлоридные соли антибиотического соединения
TH1701007800A (th) ตัวยับยั้งเมทัลโล-บีตา-แลคทาเมส
EA201990738A1 (ru) Соединения-ингибиторы бета-лактамаз